<DOC>
	<DOCNO>NCT02218762</DOCNO>
	<brief_summary>The Fluticasone Propionate/Salmeterol combination ( FSC ) dose 100/50 microgram ( mcg ) twice daily DISKUS inhaler ( also know ACCUHALER速 , Ddpi ) inhaler recognise licensed therapy treatment asthma . GlaxoSmithKline ( GSK ) develop ROTAHALER/ ROTACAPS速 ( Rdpi ) inhaler alternative treatment option asthmatic patient . This study Phase I , randomise , double-blind , double-dummy , two- treatment , four-way cross-over ( replicate design ) , two sequence , repeat dose , two centre study mild moderate asthmatic compare pharmacokinetics pharmacodynamics fluticasone proprionate/salmeterol ( 100/50 mcg ) deliver via Rdpi versus Ddpi . A total 58 subject enrol ensure 52 subject complete dose occasion . Each subject allocate one two treatment sequence participate four treatment period , receive treatment twice . DISKUS , ACCUHALER , ROTAHALER ROTACAPS register trademark GSK group company .</brief_summary>
	<brief_title>A Study Patients With Moderate Asthma Compare Pharmacokinetics Pharmacodynamic Effects Fluticasone Propionate Salmeterol Delivered Via ROTAHALER速 Inhaler Relative DISKUS速 Inhaler</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Subjects know physician diagnosis asthma best Forced Expiratory Volume 1 Second ( FEV1 ) &gt; 70 % predict normal value Screening visit . Percent predict calculate use European Respiratory Society Global Lung Function Initiative reference equation . Subjects must abstain short act beta2 agonist ( SABA ) use 6 hour prior Screening visit . During screen visit , subject must either demonstrate presence reversible airway disease , define increase FEV1 &gt; =12.0 % baseline absolute change &gt; =200 millilitre ( mL ) within 60 minute follow 4 inhalation albuterol/salbutamol inhalation aerosol ( equivalent nebulized treatment albuterol/salbutamol solution ) absence reversibility document evidence physician diagnose asthma least 6 month Male/females age 18 65 year age inclusive , time signing informed consent . Body weight &gt; = 50 kilogram ( kg ) body mass index ( BMI ) within range 18 35.0 kilogram/square meter ( kg/m^2 ) ( inclusive ) . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy definition , `` document '' refers outcome investigator's/designee 's review subject 's medical history study eligibility , obtain via verbal interview subject subject 's medical record ; postmenopausal define 12 month spontaneous amenorrhea . In questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 milliinternational unit per/millilitre ( MIU/mL ) estradiol &lt; 40 picogram/millilitre ( pg/mL ) ( &lt; 147 picomoles per liter [ pmol/L ] ) confirmatory . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method , wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . ; Childbearing potential negative pregnancy test determine serum human chorionic gonadotropin ( hCG ) test screen urine hCG test prior dosing AND ; Agrees use one contraception method appropriate period time ( determined product label investigator ) prior start dose sufficiently minimize risk pregnancy point . Female subject must agree use contraception followup visit . ; OR samesex partner , prefer usual lifestyle . Capable give write informed consent , include compliance requirement restriction list consent form Subjects current nonsmoker pack history &lt; =10 pack year . A subject may use inhale tobacco product within past 3 month ( i.e. , cigarette , cigar pipe tobacco ) . [ number pack year = ( number cigarette per day / 20 ) x number year smoke ] . Alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; = 1.5x Upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Based single average correct QT interval ( QTc ) value triplicate electrocardiogram ( ECGs ) obtain brief recording period : QT duration correct heart rate Fridericia 's formula ( QTcF ) &lt; 450 millisecond ( msec ) ; QTcF &lt; 480 msec subject Bundle Branch Block . Asthma therapy : Subjects must current therapy least eight week stable dose four week prior screen visit : 1 . Subjects fluticasone propionate/salmeterol combination 100/50 microgram ( mcg ) treatment via DISKUS inhaler prior study allow remain treatment regimen randomization provide eligibility criterion meet . ; 2 . Subjects treatment fluticasone propionate/salmeterol combination 125/25 mcg via meter dose inhaler require switch fluticasone propionate/salmeterol combination 100/50 mcg via GlaxoSmithkline ( GSK ) provide DISKUS inhaler 14 28 day prior randomization ; 3 . Subjects low dose inhaled corticosteriod ( ICS ) monotherapy ( total daily dose fluticasone propionate 250 total daily dose mcg ICS equivalent e.g . budesonide 400 mcg total daily dose ) switch fluticasone propionate/salmeterol combination 100/50 mcg via GSKprovided DISKUS inhaler 14 28 day prior randomization ; 4 . Subjects medium dose ICS monotherapy ( great 250 500 mcg fluticasone propionate total daily dose ICS equivalent e.g . budesonide great 400 mcg 800 mcg total daily dose ) switch fluticasone propionate/salmeterol combination 100/50 mcg twice daily via GSKprovided DISKUS inhaler 28 day prior randomization ; 5 . Subjects low dose Symbicort ( dose great 400/12 mcg total daily dose ) switch fluticasone propionate/salmeterol combination 100/50 mcg via GSKprovided DISKUS inhaler 14 28 day prior randomization . Criteria Based Upon Medical Histories Any clinically relevant medical condition abnormality identify screen medical assessment procedure , physical examination , laboratory assessment ( include clinical chemistry haematology ) , opinion Investigator and/or GSK Medical Monitor likely affect safety subject and/or interfere study procedure outcomes . Acute exacerbation asthma last 6 month prior Screening visit . Subjects treatment fluticasone propionate either monotherapy combination total daily dose high 500 mcg budesonide monotherapy combination total daily dose high 800 mcg beclomethasone ( CFC ) total daily dose high 1000 mcg beclomethasone ( HFA ) total daily dose high 400mcg exclude study Subjects significant pulmonary disease ( pneumonia , pneumothorax , atelectasis , pulmonary fibrotic disease , bronchopulmonary dysplasia , chronic bronchitis , emphysema , chronic obstructive pulmonary disease , respiratory abnormality asthma ) . Use oral/injectable/depot corticosteroid indication within 3 month prior Screening visit . Use anti immunoglobulin E ( AntiIgE ) ( e.g . Xolair ) period prior screen . Use intranasal steroid ( INS ) . To eligible study , patient INS therapy require switch nonINS therapy screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . History regular alcohol consumption within 6 month study define : For Australian site : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit ( = standard drink ) equivalent 10 g alcohol : 270 mL full strength beer ( 4.8 % ) , 375 mL mid strength beer ( 3.5 % ) , 470 mL light beer ( 2.7 % ) , 250 mL premix full strength spirit ( 5 % ) , 100 mL wine ( 13.5 % ) 30 mL spirit ( 40 % ) ; For South African site : An average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 gram ( g ) alcohol : halfpint ( approximately 330 mL ) beer , 1 glass ( 125 mL ) wine 1 ( 25 mL ) measure spirit . A known suspected history drug abuse within 12 month Screening visit . History sensitivity heparin heparininduced thrombocytopenia . History sensitivity salbutamol study medication , component thereof ( include severe milk protein allergy ) history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Criteria Based Upon Diagnostic Assessments A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive prestudy drug screen . A positive test Human Immunodeficiency Virus ( HIV ) antibody . Subjects know abnormal level serum cortisol A subject eligible he/she clinical visual evidence oral candidiasis prior randomisation Where participation study would result donation blood blood product excess 500 mL within 56 day period . Lactating female . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Grapefruit grapefruit juice contain product exclude 2 week prior randomisation collection final blood sample treatment period 4 . Drugs inhibit cytochrome P450 isoform , 3A4 ( CYP3A4 ) , exclude 2 week prior randomisation collection final blood sample treatment period 4 . CYP3A4 inhibitor include cimetidine , clarithromycin , erythromycin , ciprofloxacin , ritonavir , ketoconazole , azole antifungal . Use prescription nonprescription drug , vitamin , herbal dietary supplement , within seven day 5 halflives ( whichever longer ) prior first dose study medication , opinion Principal Investigator , may interfere study outcome . Specifically , calcium vitamin D supplement bisphosphonates allow throughout study . Subjects , , opinion Investigator , able comply protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Fluticasone propionate/salmeterol capsule-based inhaler</keyword>
	<keyword>replicate cross-over design</keyword>
	<keyword>Respiratory</keyword>
	<keyword>asthma</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Fluticasone propionate/salmeterol</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Fluticasone propionate/salmeterol multi-dose dry powder inhaler</keyword>
</DOC>